Chanuvati T, Viranuvatti V, Pongpipat D
Gastroenterology. 1975 May;68(5 Pt 1):1261-4.
A study of 221 patients revealed that detectable hepatitis B surface antigen (HBS Ag) was found in 16.3% of 49 patients who had hepatoma associated with cirrhosis. None of the 8 hepatoma patients without cirrhosis had detectable HBS Ag in the serum. When known causes of cirrhosis were excluded, HBS Ag was present in 18% of 22 patients. Positive alpha-1-fetoprotein (AFP) was found in 25 of 49 cases (51%) of hepatoma with cirrhosis but was found only in 1 of 8 cases (12.5%) of hepatoma without cirrhosis. Of 25 patients whose AFP was positive, HBS Ag was also present in 7. The latter was detected in only 1 of 24 patients in whom AFP was not detected. This study suggests that HBS Ag is closely associated with hepatomas in cirrhotic patients but not in noncirrhotic patients with hepatoma.
一项针对221名患者的研究显示,在49例伴有肝硬化的肝癌患者中,16.3%检测到乙肝表面抗原(HBS Ag)。8例无肝硬化的肝癌患者血清中均未检测到可检测的HBS Ag。排除已知的肝硬化病因后,22例患者中有18%存在HBS Ag。49例伴有肝硬化的肝癌患者中有25例(51%)甲胎蛋白(AFP)呈阳性,但8例无肝硬化的肝癌患者中只有1例(12.5%)呈阳性。在AFP呈阳性的25例患者中,7例也存在HBS Ag。在AFP未检测到的24例患者中,仅1例检测到HBS Ag。这项研究表明,HBS Ag与肝硬化患者的肝癌密切相关,但与无肝硬化的肝癌患者无关。